Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vor’s President and Chief Executive Officer, and Nathan Jorgensen, Ph.D., Vor’s Chief Financial Officer, will be participating in two upcoming virtual investor conferences:
Stifel 2021 Virtual Healthcare Conference
Fireside Chat Date: Monday, November 15, 2021
Time: 4:00 PM ET
Evercore ISI 4th Annual HealthCONx Virtual Conference
Fireside Chat Date: Thursday, December 2, 2021
Time: 10:55 AM ET
A live webcast of both fireside chats can be accessed via the Investors section of the Company's website at www.vorbio.com. An archived replay of each webcast will also be available.
About Vor Biopharma
Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contacts:
Investors:
Chris Brinzey
ICR Westwicke
+1 339-970-2843
chris.brinzey@westwicke.com
Media:
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
| Last Trade: | US$0.14 |
| Daily Change: | -0.02 -15.00 |
| Daily Volume: | 2,928,193 |
| Market Cap: | US$16.940M |
March 20, 2025 January 08, 2025 December 27, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
